Stem cell culture is the process of growing stem cells outside the body under carefully controlled conditions, and it underpins nearly every advance in regenerative medicine, drug testing, and disease research happening today. The process involves far more than placing cells in a dish and hoping they multiply. From the moment cells are harvested from tissue to the point they become beating heart cells or functional neurons, every variable matters: the liquid medium they sit in, the surface they attach to, the oxygen they breathe, and the physical forces acting on them. Getting any of these wrong can push cells to lose their special properties, differentiate prematurely, or accumulate dangerous genetic changes.
Where Stem Cells Come From and How They Are Isolated
Stem cells used in culture come from a range of sources. Embryonic stem cells are derived from early-stage embryos, where they can divide indefinitely while retaining the ability to become any cell type in the body.1PubMed Central. Pluripotent and Multipotent Stem Cells and Current Therapeutic Applications: Review Induced pluripotent stem cells, or iPSCs, are made by reprogramming ordinary adult cells (often skin or blood cells) back into a stem-like state. Adult stem cells, such as mesenchymal stem cells found in bone marrow and fat tissue, are more limited in what they can become but are easier to obtain ethically and are already used in clinical settings.
Once tissue is collected, the stem cells need to be separated from the other cell types mixed in with them. Two main labeling methods dominate. Fluorescence-activated cell sorting, or FACS, tags cells with fluorescent antibodies and then sorts them one by one based on how they glow. It produces very pure populations, reaching roughly 95% or higher, but the equipment is expensive and processes only around ten million cells per hour. Magnetic bead sorting, known as MACS, coats cells with antibody-linked magnetic particles and pulls them out with a magnet. It is far faster, handling around a hundred billion cells per hour, but the resulting purity sits closer to 75%, and leftover magnetic beads can interfere with the purified cells.2PubMed Central. Stem Cell Separation Technologies – Section: Traditional Separation Methods A simpler, label-free approach called pre-plating takes advantage of the fact that stem cells tend to stick to culture dishes faster than other cells. This technique has been used to enrich mesenchymal stem cells from bone marrow and to isolate stem cells from liposuction fat.2PubMed Central. Stem Cell Separation Technologies – Section: Traditional Separation Methods
Feeding the Cells
Culture medium is the liquid environment that supplies stem cells with nutrients, hormones, and signaling molecules. Its composition determines whether the cells stay in their undifferentiated state or begin turning into something else. One of the most critical ingredients for human embryonic stem cells is a growth factor called FGF2 (also known as basic fibroblast growth factor). Research comparing different concentrations found that low doses failed to keep embryonic stem cells alive beyond three passages, while a concentration of 100 ng/ml sustained them through more than 160 population doublings over several months.3PubMed Central. Basic fibroblast growth factor support of human embryonic stem cell self-renewal One reason the concentration needs to be so high in simple medium is that FGF2 degrades faster without the stabilizing factors present in conditioned medium, the nutrient broth left behind by feeder cells.
Researchers have also explored ways to deliver FGF2 without dissolving it in the liquid. One approach conjugates the growth factor directly onto the culture surface so that cells receive the signal through contact rather than from the surrounding fluid. Human iPSCs grown on these FGF2-coated surfaces maintained their pluripotency and their ability to form all three embryonic tissue layers through at least ten passages, even in medium containing no dissolved FGF2 at all.4Regenerative Biomaterials. Material surface conjugated with fibroblast growth factor-2 for pluripotent stem cell culture and differentiation – Section: Results and discussion Surface-delivered signals like these could eventually simplify large-scale manufacturing by reducing the need to constantly replenish expensive growth factors in the medium.
Surfaces, Scaffolds, and What Cells Stick To
Stem cells do not float freely in most culture systems. They anchor to a surface, and the physical and chemical properties of that surface influence whether they stay undifferentiated, start dividing, or begin specializing. Early culture protocols relied on biological coatings made of proteins extracted from animal tissue, but these introduce variability and potential contamination. The field has been moving toward chemically defined, synthetic substrates that can be manufactured consistently and scaled up.5PubMed Central. New substrates for stem cell control Options now range from natural extracellular matrix proteins to engineered peptides and polymer-based scaffolds, and several synthetic peptide substrates are commercially available for researchers aiming to bring stem cell therapies into the clinic.6PubMed Central. Substrates for clinical applicability of stem cells
The Feeder Cell Question
Traditionally, stem cells were grown on top of a layer of “feeder” cells, usually mouse embryonic fibroblasts, which secrete growth factors and provide structural signals that help maintain pluripotency. Experiments comparing feeder types found that mouse embryonic fibroblasts outperformed another common feeder line (STO cells) and feeder-free conditions in sustaining high levels of key pluripotency proteins like NANOG and SOX-2 in mouse embryonic stem cells.7PubMed Central. Effects of Feeder Cell Types on Culture of Mouse Embryonic Stem Cell In Vitro
The problem is that animal-derived feeders carry the risk of transferring animal pathogens and triggering immune responses in human recipients. Human dermal fibroblasts can substitute, but they still risk contaminating the stem cell population. Research comparing all three approaches for human iPSCs concluded that feeder-free culture on matrices like Matrigel, combined with the right supplemented medium, resolves these problems and is better suited for therapeutic applications.8PubMed Central. Comparison between the cultures of human induced pluripotent stem cells (hiPSCs) on feeder-and serum-free system (Matrigel matrix), MEF and HDF feeder cell lines The trade-off is real, though: feeder-free systems demand more precise control of medium composition and surface coatings to compensate for the biological support feeders provide naturally.
Scaling Up with Bioreactors
Growing stem cells in flat dishes works for research, but clinical and industrial applications need billions of cells. Bioreactors, essentially controlled vessels with stirring or rocking mechanisms, offer a path to that scale. They do more than just hold a larger volume of cells. The mechanical forces and oxygen levels inside a bioreactor profoundly affect cell behavior. One study found that combining a low-oxygen environment (around 4% oxygen, compared to roughly 20% in the normal atmosphere) with intermittent stirring in a tank bioreactor improved heart muscle cell yields from iPSCs by about a thousandfold compared to standard oxygen and continuous stirring.9PubMed Central. Combining hypoxia and bioreactor hydrodynamics boosts induced pluripotent stem cell differentiation towards cardiomyocytes
Oxygen distribution within cell clusters is a persistent challenge. When stem cells form aggregates in culture, oxygen struggles to diffuse to the core. Human embryonic stem cell clusters smaller than 200 micrometers stayed well-oxygenated throughout, but in clusters larger than 400 micrometers, nearly a quarter of cells experienced low oxygen, and that fraction jumped to about 70% in clusters reaching 1,000 micrometers across. Stirred-suspension bioreactors performed better than static dishes at delivering oxygen to equally sized clusters, likely because agitation speeds the transfer of oxygen from the bulk liquid to each aggregate.10PLoS ONE. Oxygen Transport and Stem Cell Aggregation in Stirred-Suspension Bioreactor Cultures – Section: Results
Verifying That Cells Are What You Think They Are
After weeks or months in culture, stem cells need to prove they are still genuinely pluripotent. Researchers look for a panel of marker proteins on the cell surface and inside the nucleus, including OCT4, SOX2, NANOG, TRA-1-60, TRA-1-81, and others. When iPSCs were generated from human cord blood, for instance, all tested lines showed strong activity of alkaline phosphatase and telomerase, expressed the full set of expected pluripotency markers, maintained a normal chromosome count through more than ten passages, and survived in culture for at least twenty passages.11Cell Stem Cell. Generation of Induced Pluripotent Stem Cells from Human Cord Blood Using OCT4 and SOX2 – Section: Main Text
Markers are useful shortcuts, but the gold standard remains a functional test: can the cells actually differentiate into all cell types? International guidelines from the ISSCR state that a cell line can only be characterized as truly pluripotent if its differentiation ability is demonstrated through appropriate assays, such as forming teratomas in animal models or generating all three germ layers in a dish.12PubMed Central. A short history of pluripotent stem cells markers – Section: Discussion Markers are invaluable for routine monitoring, but they are not a substitute for this functional proof.
Three-Dimensional Culture and Organoids
Flat dishes are a crude approximation of what cells experience inside the body. Three-dimensional culture systems, particularly organoids and organ-on-a-chip platforms, aim to recreate more realistic tissue environments. Researchers have developed microfluidic chips that combine stem cell culture with high-content imaging, allowing them to track individual organoid growth, viability, and metabolic activity over days. Intestinal organoids cultured on one such chip grew faster on average than organoids in traditional dome cultures off-chip and showed comparable or slightly better viability.13Scientific Reports. A microfluidic platform for culturing and high-content imaging of adult stem cell-derived organoids
An even more ambitious approach adds vascularization. One platform established functional endothelial networks around stem-cell-derived spheroids and blood vessel organoids, culturing them on-chip for up to 30 days. These networks formed working connections with the organoids and provided intravascular perfusion, essentially acting like tiny blood supplies. Organoid growth, maturation, and function all improved when cultured with this vascularization method compared to standard approaches.14Nature Communications. A microfluidic platform integrating functional vascularized organoids-on-chip These platforms hold particular promise for drug screening and disease modeling, where researchers need tissue responses that reflect real human biology rather than cells growing in flat sheets.15PubMed Central. Microfluidic three-dimensional cell culture of stem cells for high-throughput analysis
Disease Modeling and Drug Screening
One of the most powerful applications of stem cell culture is creating “disease in a dish” models. Researchers take cells from patients with genetic diseases, reprogram them into iPSCs, and then coax those iPSCs into the affected cell type, such as neurons for a brain disorder or heart cells for a cardiac condition. This approach is especially valuable for rare diseases, where finding enough patients for traditional research is difficult.16PubMed Central. Modeling rare genetic disease with patient-derived induced pluripotent stem cells: reassessment of the minimum numbers of lines needed Patient-derived iPSCs combined with CRISPR gene editing and 3D brain organoid models have opened new windows into rare neurodevelopmental disorders caused by both single-gene and multi-gene mutations.17PubMed Central. Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies
Drug screening is a natural extension. Instead of testing compounds on animal cells that may respond differently from human tissue, researchers can test them on human stem-cell-derived cells. This has been particularly fruitful in cardiology. A study using heart cells derived from both healthy and disease-specific iPSC lines found that patients with underlying cardiac conditions show different susceptibilities to cardiotoxic drugs than healthy individuals. The authors concluded that screening with disease-specific iPSC-derived heart cells may predict adverse drug reactions more accurately than standard screening methods.18PubMed Central. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity Stem-cell-based assays also offer the potential for more accurate environmental toxicant risk assessment and reduced reliance on animal models.19PubMed. Stem cell models for drug discovery and toxicology studies
Regenerative Medicine and Tissue Engineering
The most visible promise of stem cell culture is repairing damaged tissues in living patients. Clinical trials for age-related macular degeneration have been testing transplants of retinal pigment epithelium cells derived from both embryonic stem cells and iPSCs. In a phase 1/2a study, 15 patients received a subretinal implant of embryonic-stem-cell-derived retinal cells on an ultrathin scaffold. The surgery was well-tolerated, and patients trended toward visual improvement. A separate trial used autologous iPSC-derived retinal cell sheets, where the patient’s own skin cells were reprogrammed; one-year results showed safety and stability of the transplanted sheets with no evidence of visual worsening.20PubMed Central. AMD and Stem Cell-Based Therapies – Section: AMD clinical trials
Three-dimensional bioprinting takes this further by combining stem cells with printable scaffold materials. Researchers have printed human adipose stem cells alongside composite scaffolds made of polymer and bioactive glass, creating porous structures with pore sizes ranging from 100 to 300 micrometers that mimic the three-dimensional environments cells encounter in the body.21PubMed Central. 3D bioprinting of stem cells and polymer/bioactive glass composite scaffolds for bone tissue engineering In a more targeted example, a 3D-printed hydrogel scaffold loaded with iPSC-derived mesenchymal stem cells was implanted to repair injured uterine lining. The scaffold significantly increased the survival of transplanted cells compared to injecting cells alone and promoted the regeneration of endometrial tissue, glands, and blood vessels, partially restoring the uterus’s ability to support embryo implantation.22PubMed. 3D Bioprinting a human iPSC-derived MSC-loaded scaffold for repair of the uterine endometrium
Safety Risks in Long-Term Culture
Stem cells that are kept growing for extended periods can accumulate genetic changes, and some of those changes look disturbingly like early steps toward cancer. In experiments involving over 100 continuous passages, researchers found that both enzymatic passaging (using enzymes to detach cells from the dish) and feeder-free culture were associated with genetic instability and higher rates of cell proliferation. Across most culture-condition combinations they tested, recurrent deletions appeared in the region of the genome containing TP53, a major tumor suppressor gene. These deletions were linked to reduced TP53 activity and downstream changes consistent with weakened tumor-suppression pathways.23PLoS ONE. Increased Risk of Genetic and Epigenetic Instability in Human Embryonic Stem Cells Associated with Specific Culture Conditions – Section: Results The one exception was mechanical passaging on feeder layers, the most labor-intensive method and the hardest to scale. This tension between scalability and genomic safety remains unresolved and is a central concern for clinical translation.
Manufacturing at Scale Under GMP Standards
Bringing stem cell therapies to patients means producing cells under Good Manufacturing Practice (GMP) conditions, the same quality framework used for conventional drugs. This requires fully documented materials, traceable reagents, and validated processes at every step. Early GMP banks of human embryonic stem cells were produced on mouse feeder cells, but the field is pushing toward eliminating all animal-derived materials to avoid pathogen risks.24PubMed. GMP scale-up and banking of pluripotent stem cells for cellular therapy applications A parallel challenge is replacing fetal bovine serum in culture medium with humanized or serum-free alternatives that meet regulatory standards.25PubMed Central. Automated Manufacturing Processes and Platforms for Large-scale Production of Clinical-grade Mesenchymal Stem/ Stromal Cells
Cryopreservation, the freezing and long-term storage of cell banks, introduces its own difficulties at clinical scale. Small-volume freezing is well-controlled using specialized rate-controlled freezers, but scaling up to the large volumes needed for therapy brings heat transfer problems and difficulties controlling ice crystal formation, both of which affect whether cells survive thawing.26PubMed Central. GMP cryopreservation of large volumes of cells for regenerative medicine: active control of the freezing process
Epigenetic Memory and Why the Starting Cell Matters
When adult cells are reprogrammed into iPSCs, you might expect them to become a blank slate. They do not, entirely. iPSCs retain an “epigenetic memory” of the tissue they came from, meaning chemical marks on their DNA that influence which genes are easy or hard to turn on. iPSCs made from blood cells, for instance, carry different residual methylation patterns than iPSCs made from skin or neural cells, and these differences affect what the cells can most readily become. Blood-derived iPSCs differentiate more efficiently into blood cells, while iPSCs from non-blood sources retain methylation at the genetic regions needed for blood formation and show reduced blood-forming potential.27PubMed Central. Epigenetic memory in induced pluripotent stem cells – Section: Discussion
This is not just a curiosity. Extended passaging of some iPSC clones did not improve their resemblance to true embryonic stem cells, suggesting that for certain cell lines, the epigenetic memory is persistent rather than something that fades over time.28PubMed Central. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells The practical implication is that choosing the right starting tissue for reprogramming may matter more than refining culture conditions after the fact, especially when the goal is to differentiate iPSCs into a specific therapeutic cell type.
Engineering “Universal Donor” Stem Cells
A major obstacle to using stem-cell-derived therapies widely is immune rejection. A patient’s body will attack transplanted cells carrying unfamiliar surface proteins, the same way it rejects a mismatched organ transplant. Making personalized iPSCs from each patient’s own cells avoids this problem but is slow, expensive, and hard to scale. An alternative is to engineer “hypoimmunogenic” or “universal donor” cell lines by using CRISPR gene editing to knock out the genes encoding the surface proteins that trigger immune recognition.
Researchers have generated iPSC lines with targeted disruption of key immune-recognition genes, including HLA-A, HLA-B, and HLA-DRA. One such triple-knockout clone demonstrated immune evasion in testing: central memory T cells and effector memory T cells showed no proliferation in response to it, while the cells retained all their normal stem cell characteristics.29Experimental & Molecular Medicine. Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout – Section: Results If these lines prove safe over time, they could serve as off-the-shelf starting material for a wide range of therapies, eliminating the need to create custom iPSCs for each individual patient.30PubMed Central. Universal cell donor lines: A review of the current research
Hidden Variability Within a Single Culture
Even a culture that looks uniform under the microscope may be surprisingly heterogeneous at the molecular level. Single-cell RNA sequencing, which reads gene activity in thousands of individual cells, has revealed that human pluripotent stem cell populations contain subgroups with distinct gene-expression profiles. These differences can arise from genetic and epigenetic abnormalities accumulated during long-term culture or during the reprogramming process itself.31PubMed Central. Single cell heterogeneity in human pluripotent stem cells
This matters practically because not every cell in a culture dish responds the same way to differentiation signals. When researchers tracked the differentiation of embryonic-stem-cell-derived limbal stem cells (used for corneal repair) at single-cell resolution over time, they found significant variation in the expression of established limbal stem cell markers across subpopulations of the differentiated cells.32PubMed Central. Time-course single-cell RNA sequencing reveals transcriptional dynamics and heterogeneity of limbal stem cells derived from human pluripotent stem cells Such heterogeneity has implications for therapeutic manufacturing: if only a fraction of the cells in a batch are the desired type, quality control must be sensitive enough to detect and quantify the off-target cells before the product reaches a patient.
Ethical and Regulatory Landscape
The ethics of stem cell culture remain contentious, particularly around embryonic stem cells, which require the destruction of a human embryo. iPSCs sidestepped much of that controversy by using adult cells as starting material, but the field has circled back to difficult questions with the emergence of “embryoids,” lab-grown structures that mimic early embryonic development. A systematic review of the literature identified 56 papers discussing the ethical, legal, and regulatory implications of embryoid research, using 53 distinct terms just to name these structures, which gives a sense of how fast the science is outpacing the language and rules governing it.33PubMed Central. Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature
Governance varies widely across countries. In 2021, the International Society for Stem Cell Research revised its guidelines for stem cell research and clinical translation, providing updated best practices. A comparison of 11 research-intensive countries found meaningful differences between national policies and these international guidelines, creating a patchwork where work permitted in one country may be restricted or illegal in another.34PubMed. Modeling policy development: examining national governance of stem cell-based embryo models For researchers, this means the regulatory environment can shape experimental design as much as the science itself, and for patients, it means access to emerging stem-cell therapies depends partly on where they live.